Pharmaceutical Technology

SEPTEMBER 22, 2022

A late-stage asset of Spero, tebipenem HBr is being developed as the first oral carbapenem antibiotic to treat cUTIs, including pyelonephritis, which are caused by specific bacteria. Under the deal, GSK will obtain an exclusive licence for the development and marketing of tebipenem pivoxil HBr in all countries.

Bacteria 147

Bacteria Marketing Trials Clinical Development 147

Pharmaceutical Technology

MAY 31, 2023

Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Hepatocellular Carcinoma. It comprises of a single strain of killed and intact, non-pathogenic gram bacteria with reduced LPS-endotoxin activity. it is administered through intravenous route.

Drug Delivery Systems 130

Drug Delivery Systems Drug Delivery Bacteria Drugs 130

Drug Discovery World

AUGUST 4, 2023

.” The announcement follows a report by University of Queensland researchers, which warned a global crisis of antibiotic resistance is inevitable , despite promising developments in new antibiotics.

Clinical Development 52

Clinical Development Development Bacteria Drugs 52

Drug Discovery World

JULY 12, 2022

MRSA is becoming more common among the pathogenic bacteria that cause lung infections in cystic fibrosis patients. Destiny Pharma is currently preparing XF-73 for Phase III clinical development to prevent post-surgical Staphylococcal infections. It’s thought that around 25% of people with the disease are infected with MRSA.

Bacteria 52

Bacteria Genetic Disease Genetics Clinical Development 52

Roots Analysis

FEBRUARY 27, 2024

The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization. How many of the ADCs in development have pyrrolobenzodiazepine (PBD) as warhead: Pyrrolobenzodiazepines are a class of compounds that kill cells by binding their DNA and interfering with replication.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

pharmaphorum

DECEMBER 4, 2020

Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development. VLA15 is the only active Lyme disease vaccine in clinical development today, and covers six strains that are prevalent in North America and Europe.

Vaccination 117

Vaccination Vaccine Bacterium Protein 117

Pharmaceutical Technology

JUNE 6, 2023

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others.

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

Drug Discovery World

JULY 12, 2022

WHO has released the first-ever report 1 looking at the pipeline of vaccines currently in development to fight infections caused by (AMR) . The report highlights the need to accelerate clinical trials for AMR-related vaccines in late-stage development and also to maximise the use of current existing vaccines. .

Vaccination 52

Vaccination Vaccine Bacteria Development 52

pharmaphorum

SEPTEMBER 30, 2020

Funding will support completion of an ongoing phase 2 trial and further clinical development of VE303, an orally-administered live biotherapeutic product (LBP) consisting of eight bacterial strains designed to therapeutically reset a patient’s gut microbiota to stop C.

Bacteria 52

Bacteria Production Trials Clinical Development 52

pharmaphorum

DECEMBER 15, 2020

Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through phase 2 clinical trials, as well as manufacturing and regulatory preparation for phase 3. These are capable of mobilising the immune system against GBS bacteria and preventing invasion of epithelial and endothelial cell barriers.

Bacteria 52

Bacteria Vaccination Vaccine Immune Response 52

Camargo

JULY 27, 2021

When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

pharmaphorum

JUNE 20, 2022

Valneva is on the hook for 40% of development costs, up from 30%, but also stands to receive milestone payments of up to $100 million based on sales performance which were not included in the original agreement. The shot targets the outer surface protein A (OspA) of the Borrelia burgdorferi bacteria that causes Lyme disease.

Vaccination 91

Vaccination Vaccine Licensing Licensing 91

pharmaphorum

SEPTEMBER 28, 2021

VLA15 targets the outer surface protein A (OspA) of the Borrelia burgdorferi bacteria that causes Lyme disease, a tick-borne infection that causes a characteristic rash that can be accompanied by flu-like symptoms and – in some cases – debilitating tiredness and aches that can last for years.

Vaccination 103

Vaccination Vaccine Bacteria Protein 103

Drug Discovery World

NOVEMBER 18, 2022

Overall, the WHO’s assessment of antibacterial products in clinical development 4 highlights the lack of activity in the sector, stating that the clinical pipeline and recently approved antibiotics “are insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance.” .

Bacteria 52

Bacteria Drugs Development Research 52

Drug Discovery World

AUGUST 12, 2022

VLA15 is the only Lyme disease vaccine candidate currently in clinical development. It works by targeting the outer surface protein A (OspA) of the bacteria that cause Lyme disease. Participants will receive three doses of VLA15 or a saline placebo, followed by a booster dose. .

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

The Pharma Data

MARCH 8, 2021

VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. About VLA 15. burgdorferi naïve volunteers. About Lyme Disease.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

pharmaphorum

APRIL 26, 2022

There’s only one vaccine candidate for tick-borne infection Lyme disease in clinical development – Valneva and Pfizer’s VLA15 – and it has just moved another step closer to being available.

Vaccination 67

Vaccination Vaccine Bacteria Trials 67

The Pharma Data

APRIL 26, 2022

About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

The Pharma Data

JANUARY 4, 2021

In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria.

Bacteria 52

Bacteria Containment Development Protein 52

The Pharma Data

DECEMBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Polyphor AG (SIX: POLN) today announced that the UK Medicines and Healthcare products regulatory agency (MHRA) has granted a CTA (Clinical Trial Authorization) to start the first-in-human Phase I study of its novel class antibiotic murepavadin, delivered via the oral inhalation route.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Bacteria 40

The Pharma Data

JULY 21, 2021

VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. The program was granted Fast Track designation by the U.S.

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

XTalks

AUGUST 18, 2021

Also important are the environmental changes that take place in the lung tissue during infection with SARS-CoV-2; the buildup of fluid and pus in pulmonary alveoli can provide a hospitable breeding ground for pathogenic bacteria. This is consistent with autopsy reports from previous pandemics, including the influenza pandemic of 1918.

Development 105

Development Bacteria Drugs Vaccination 105

The Pharma Data

DECEMBER 13, 2020

In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Bacteria 52

Drug Discovery World

JANUARY 19, 2023

Connie Peyrottes, Senior VP clinical development at Abionyx Pharma, added: “The positive results from this Phase IIa trial show CER-001 has the potential to be a gamechanger for critical illnesses marked by inflammation and organ failure across different high mortality clinical indications which continue to have high unmet medical needs.”

Drugs 52

Drugs Trials Clinical Trials Clinical Trials 52

The Pharma Data

JULY 18, 2021

Pneumococcal disease is an infection caused by bacteria called Streptococcus pneumoniae, or pneumococcus. Different strains of this bacteria are called serotypes. Invasive pneumococcal disease (IPD) occurs when the bacteria infect parts of the body that are usually free from germs.

Immune Response 52

Immune Response Vaccination Vaccine FDA Approval 52

The Pharma Data

DECEMBER 13, 2020

The Nature Communications publication titled, “Immunotherapy with an engineered bacteria by targeting the STING pathway for anti-tumor immunity,” details the engineering and characterization of SYNB1891 (Leventhal, D.S., SYNB1891 is being evaluated in a Phase 1 clinical trial. Sokolovska, A.,

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

Pfizer

FEBRUARY 16, 2023

While VLA15 is still under investigation, to date the companies have been encouraged by the data from the Phase 2 clinical studies, which demonstrated strong immunogenicity and acceptable safety and tolerability profiles. 2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Delveinsight

DECEMBER 16, 2020

Caused by bacteria, viruses, and parasites, Sexually transmitted diseases (STDs) are a global health burden and it seems they are likely to maintain their status of being so in coming years also, primarily due to the lack of knowledge, and awareness. The medications can cure some of the STDs caused by bacteria, yeast, or parasites.

Bacteria 52

Bacteria Development Genotype Vaccination 52

The Pharma Data

DECEMBER 2, 2020

Additionally, HZI is looking to develop a new treatment for difficult-to-treat Pseudomonas aeruginosa infections in cystic fibrosis patients. aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. to establish a new joint venture company, Nanjing AuroRNA Biotech Co., in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Delveinsight

JULY 27, 2021

Seres was in a joint partnership with Nestlé Health Science (NHS) for development of different bacteria-based drugs, many of which are under clinical development. With another type of treatment already in the developing phase, there are still hopes for carrying the drug forward.

Vaccination 96

Vaccination Vaccine Trials Manufacturing 96

The Pharma Data

OCTOBER 22, 2020

The Company intends to use the net proceeds from this offering to support its planned New Drug Application submission for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with quinolone-resistant pathogens, the continued clinical development of sulopenem, and for working capital and general corporate purposes.

In-Vitro 40

In-Vitro Clinical Trials Clinical Trials Sales 40

The Pharma Data

OCTOBER 26, 2020

The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The Company’s pipeline is highlighted below: Aridis’ Pipeline. AR-301 (VAP).

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

The Pharma Data

OCTOBER 19, 2020

“Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Pneumococcal Disease.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. CARB-X will provide Polyphor with initial funding of up to $2.62

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52

Drug Discovery World

MAY 6, 2024

Professor Dr Carla van Gils, Director of KWF, comments: “Many of academia’s most innovative agents can be difficult to bring into clinical development. Partnering with the Centre for Drug Development enables us to jump into the bench-to-bedside gap and fast track academic findings into clinical trials.

Drugs 59

Drugs Life Science Gene Editing Gene 59

XTalks

APRIL 12, 2021

The last update on the clinical development of inzomelid came in December when a pharmacokinetic (PK) study initiated by Inflazome in early April was withdrawn by Roche, who attributed it to a “strategic decision by sponsor.”. According to Neuropore’s pipeline page, both UCB0599 and NPT520-34 remain in Phase I clinical development.

Gene Therapy 96

Gene Therapy Gene Trials Development 96

The Pharma Data

OCTOBER 19, 2020

Caris Precision Oncology Alliance members also have access to the Caris Pharmatech oncology trial network, which can help reduce the time it takes to identify and connect appropriate patients with novel targeted cancer therapies in clinical development.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52